Showing results (181-190 of 233) with videos related to

Sort By:
Pageof 24
Lung Cancer (Amsterdam, Netherlands)|July 11, 2015
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave RoussyM Kossai, B Duchemann, C Boutros, et al.
Lung Cancer (Amsterdam, Netherlands)|September 11, 2020
Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasmsM Rubino, J Y Scoazec, E Pisa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2004
Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcomeJ-P Spano, F Andre, L Morat, et al.
Lung Cancer (Amsterdam, Netherlands)|January 1, 2021
Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitorsB Abbar, V De Castelbajac, P Gougis, et al.
Respiratory Medicine and Research|September 27, 2020
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapyC Lefebvre, E Martin, L E L Hendriks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2015
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancerE Deutsch, C Le Péchoux, L Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2013
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancerB Besse, R S Heist, V A Papadmitrakopoulou, et al.
Chest|September 26, 2025
The Impact of Dual Cannabis and Tobacco Smoking in Young Patients With Lung Cancer: Results From the Prospective "Environment and Lung Cancer" StudyPauline Pradère, A Marinello, D Vasseur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2011
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)T C Gauler, B Besse, A Mauguen, et al.
ESMO Open|March 5, 2023
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancerC M Rudin, A Cervantes, A Dowlati, et al.
Pageof 24